Search Type: drug or dietary supplement name
Search Term: canagliflozin (INVOKAMET, INVOKANA)

Worst Pills, Best Pills Newsletter Articles

Worst Pills, Best Pills Newsletter Articles

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a primary subject of discussion
  • Potentially Dangerous Digoxin Drug Interactions [hide all summaries]
    (November 2018)
    Read about the numerous medications that can interact with digoxin, a drug commonly prescribed for heart failure and atrial fibrillation. These interactions can result in either digoxin toxicity or decreased digoxin effectiveness depending on the other drug being used concomitantly.
  • Diabetes Drug Canagliflozin Doubles Risk of Amputations, FDA Warns [hide all summaries]
    (October 2017)
    Canagliflozin is one of three medications in the newest diabetes drug class. In this article, we discuss why the FDA recently required that a black-box warning about the risk of amputations be added to the product labeling of canagliflozin.
  • FDA Issues Multiple Warnings For Newest Class of Diabetes Drugs [hide all summaries]
    (October 2016)
    Over the past year, the Food and Drug Administration has issued a series of new warnings about serious and, in some cases, potentially fatal events linked to the newest class of diabetes drugs. These drugs, known as "flozins," are being heavily promoted in TV ads. Learn more about these newly identified dangers and why you should avoid all flozins.
  • News Brief for February 2016 [hide all summaries]
    (February 2016)
    In our news brief this month, we report on two recent warnings issued by the Food and Drug Administration about the diabetes drugs known as SGLT2 inhibitors, more commonly known as “flozins.” This family of drugs, all designated as Do Not Use, includes canagliflozin (INVOKAMET, INVOKANA), dapagliflozin (FARXIGA) and empagliflozin (JARDIANCE).
  • Risks but No Benefits to Taking Newest Drugs For Type 2 Diabetes [hide all summaries]
    (August 2015)
    The airwaves are filled with ads promoting the newest class of diabetes medications, often referred to as “flozins.” In this article, we review the serious safety concerns that have prompted us to designate all flozins as Do Not Use.
  • Public Citizen Shines a Light on Off-Label Promotion of Diabetes Drugs [hide all summaries]
    (July 2015)
    In a recent complaint to the FDA, we took several makers of diabetes drugs to task for direct-to-consumer ads that promote the drugs for unapproved uses. Find out the names of the drugs targeted in our complaint and the nature of the off-label uses being promoted in the ads.
  • Year in Review: Troubling New Drug Approvals of 2013 [hide all summaries]
    (March 2014)
    Learn about new drugs approved by the FDA in 2013 that Worst Pills Best Pills has identified as dangerous or ineffective. The drugs include two for diabetes, two for chronic obstructive pulmonary disease and an over-the-counter drug for overactive bladder, among others.
  • The New Diabetes Drug Canagliflozin (INVOKANA) [hide all summaries]
    (February 2014)
    Do not use the newly approved diabetes drug INVOKANA. It offers no benefits over existing drugs but can result in serious risks, including hypotension and impaired kidney function, outlined in the article.

Additional Information from Public Citizen

Search results below include Additional Information from Public Citizen where your selected drug is a primary subject of discussion
  • Letter to FDA on the Off-Label Promotion of Several Diabetes Drugs (HRG Publication #2250) [hide all summaries]
    Public Citizen calls on the Food and Drug Administration’s (FDA’s) Office of Prescription Drug Promotion to halt the dissemination of direct-to-consumer advertisements for five prescription drugs approved only for the treatment of Type 2 diabetes. The ads promote the drugs for the off-label uses of weight loss and blood pressure reduction. Public Citizen also calls on the agency to fine the companies responsible for issuing the ads, an action that it has never before taken in response to such violative ads.

SHOW secondary search results for canagliflozin (INVOKAMET, INVOKANA)

Copyright © 2018 Public Citizen's Health Research Group. All rights reserved.